Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Under the deal, both companies will partner on the research and preclinical studies, which will be funded by Moderna.

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

Pharmaceutical Technology

SEPTEMBER 29, 2022

Under the agreement, Sanofi will receive non-exclusive rights to Scribe’s CRISPR by Design platform of wholly-owned enzymes for developing ex vivo NK cell therapies. The alliance will leverage the CRISPR genome editing technologies of Scribe to facilitate in genetic modification of new natural killer (NK) cell therapeutics for cancer.

Development 130

Development In-Vivo Genome Genomics 130

Pharmaceutical Technology

MAY 17, 2023

Scribe Therapeutics has entered a strategic collaboration with Eli Lilly and Company subsidiary Prevail Therapeutics for accelerating in vivo CRISPR-based therapies to target the causes of serious neurological and neuromuscular diseases. Editorial content is independently produced and follows the highest standards of journalistic integrity.

Genetics 130

Genetics Medicine In-Vivo Gene Therapy 130

Pharmaceutical Technology

JULY 20, 2022

The alliance plans to leverage the single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology of Avista to develop intravitreal AAV capsids for a Roche-defined profile. According to the deal, Roche holds the right to analyse and licence new capsids from Avista. Avista is entitled to receive $7.5m

Gene Therapy 147

Gene Therapy Gene Development In-Vivo 147

Pharmaceutical Technology

FEBRUARY 23, 2023

Innovation S-curve for artificial Intelligence in the pharmaceutical industry In-silico drug discovery is a key innovation area in artificial Intelligence Drug research starts with the discovery stage that involves in vivo and in vitro models to shortlist lead drug compounds.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

pharmaphorum

JANUARY 29, 2021

California-based Sangamo Therapeutics is one such company that believes in the powerful potential of in vivo genome editing and regulation, together known as genome engineering, and has built up a sizable preclinical pipeline of genome regulation treatments for diseases such as Huntington’s disease and Amyotrophic lateral sclerosis (ALS).

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Pharmaceutical Technology

SEPTEMBER 14, 2022

As an autologous cell therapy, manufacturing the infusion product is a highly specialised process involving tumour harvest and the extraction and large-scale ex vivo expansion of TILs. The use of engineered immune cytokines that selectively induce the expansion of TILs is being investigated as an alternative to IL-2 stimulation.

Immune Response 246

Immune Response In-Vivo Production Manufacturing 246

Pharmaceutical Technology

SEPTEMBER 14, 2022

Additionally, RayzeBio is establishing a 28,000ft² research and development facility in San Diego, California, US. . The company is also concluding more than 200 in vivo studies to gain insights and discover new drug candidates that could provide therapeutic radioisotopes for tumour-linked antigens.

In-Vivo 130

In-Vivo Clinical Trials Clinical Trials Engineer 130

pharmaphorum

APRIL 25, 2022

Now, US researchers think one solution could be an implant that generates T cells within the body to attack the cancer. The UNC and NCSU team, led by biomedical engineer Yevgeny Brudno, report in Nature Biotechnology how they have developed an implant that can generate the CAR-T cells in vivo.

Engineer 105

Engineer In-Vivo FDA Approval Manufacturing 105

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. However, not all innovations are equal and nor do they follow a constant upward trend.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

XTalks

MAY 19, 2022

In recent years, there has been an increase in research interest for smart stents , which are stents with integrated sensors. Researchers at the Georgia Institute of Technology have recently developed a new implantable vascular monitoring system consisting of a stent and soft sensors.

Development 72

Development Research In-Vivo Engineer 72

Pharmaceutical Technology

MARCH 9, 2023

Innovation S-curve for the pharmaceutical industry Transgenic murine models is a key innovation area in pharmaceutical s Transgenic murine models refer to mice that have been genetically altered for the purposes of understanding the in vivo functions of genes.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

pharmaphorum

FEBRUARY 13, 2022

Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity. The post Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety appeared first on.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

pharmaphorum

FEBRUARY 23, 2021

Advance Cutting-Edge Research and Development with Next-Generation Cell Therapies, to Deliver Best-in-Class Products to Patients in Need. Implement logic and develop ‘decision-making’ cells: create robust, controllable activation in vivo with University of Pennsylvania and Ludwig Institute for Cancer Research Lausanne.

In-Vivo 52

In-Vivo Engineer Development Production 52

The Pharma Data

NOVEMBER 5, 2020

Drawing upon 50 years of expertise in clinical research, biopharmaceuticals, biotechnology and drug discovery, Dr. Van Kampen excels as the chief executive officer of The Van Kampen Group, which assists other companies in research and liaisons with government and industry regarding licensing products for commercial use.

Research 52

Research Vaccination Vaccine Doctor 52

XTalks

DECEMBER 20, 2023

AI and Machine Learning: Transforming Research Artificial intelligence (AI) and machine learning (ML) are revolutionizing research approaches in the life sciences. Below are some of the key trends that will be shaping the future of the life sciences in 2024 and beyond.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

XTalks

MAY 22, 2024

He was most recently Vice President of Discovery Research at Codiak Biosciences, where he led the development of a new class of therapeutics based on engineered exosomes. In this episode, Ayesha spoke with John Finn, PhD, Chief Scientific Officer at Tome Biosciences , a company developing programmable gene insertion (PGI) technology.

Gene Editing 52

Gene Editing Life Science Gene Gene Therapy 52

XTalks

AUGUST 19, 2022

XTALKS WEBINAR: How Agile Clinical Trials Unlock Universal Access to Rare Disease Research. Zynteglo is administered as a one-time treatment, with each dose consisting of a patient’s own bone marrow stem cells engineered to make functional beta-globin through insertion of working copies of the beta-globin gene.

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

The Pharma Data

JANUARY 12, 2021

KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. Working alongside KSQ will facilitate smart drug discovery and development of what we hope will be transformative new therapies for patients with intractable forms of cancer.”.

Development 52

Development Research In-Vivo Genome 52

pharmaphorum

JANUARY 25, 2022

For example, there is no need for in vivo animal or in vitro pre-clinical or non-clinical studies. The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can be applied and why investment in the area is mounting. This equated to $21.3

Medicine 111

Medicine In-Vivo In-Vitro Development 111

The Pharma Data

DECEMBER 9, 2020

With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. A solution could be at hand with Overland Pharmaceuticals. Below is a roundup of some of this week’s interesting news.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

JUNE 17, 2022

Researchers from the Institut Pasteur, Université Paris Cité, and INSERM examined 102 SARS-CoV-2 spike monoclonal antibodies cloned from the B cells of 10 COVID-19 convalescents. The research has its roots in a task force launched by the Institut Pasteur in the early days of the COVID-19 pandemic.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

Delveinsight

FEBRUARY 25, 2021

Electroporation is used for ex vivo delivery of therapies to blood and immune cells. The company’s in vivo therapies reach the eye and central nervous system via adeno-associated viruses, while its liver therapies employ lipid nanoparticles (LNPs). Beam employs three approaches to deliver its genetic medicines to cells.

DNA 52

DNA In-Vivo Genetics Medicine 52

XTalks

AUGUST 5, 2020

In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.

Gene Expression 112

Gene Expression Development RNA Drugs 112

The Pharma Data

JANUARY 4, 2021

The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections. The companies will work together on the in vivo proof of concept (POC). Gene therapy has become a clinical reality. For further information, please visit www.vigeneron.com.

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

Roots Analysis

SEPTEMBER 18, 2023

Even though, appropriately preserved biologics have immense potential for use in basic research and other medical applications, damage sustained by the membrane during freezing and thawing results in osmotic shock, which can ultimately lead to cell death.

Engineer 52

Engineer Containment In-Vivo Production 52

Roots Analysis

DECEMBER 8, 2021

Biopreservation is the exclusive biological approach designated for the preservation of cells, tissues and organs ex-vivo for the purpose of storage, shipment and transportation. Biopreservation media is one of the most crucial entity in conferring effectiveness. F) to 8°C (46.4°F).

In-Vivo 52

In-Vivo Packaging Packaging Biobanking 52

The Pharma Data

JANUARY 11, 2021

Our antibody clones in their original IgG format have shown potent neutralization activity in in vitro assays and, in the case of our lead clone, in an in vivo animal model. Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.

Antibody 52

Antibody Licensing Licensing Development 52

Roots Analysis

AUGUST 31, 2023

The applications of gene switch platforms can be broadly classified into the following two categories: Endogenous Gene Regulation Exogenous Gene Regulation Endogenous Gene Regulation The ability to regulate endogenous genes has various applications in biological research and gene therapy development.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

The Pharma Data

APRIL 22, 2023

Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A. Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A. million individuals that currently have to live with the disease.

Immune Response 40

Immune Response Engineer In-Vivo Containment 40

The Pharma Data

OCTOBER 15, 2020

Prior to joining Inozyme, Sabbagh served as the head of rare renal and musculoskeletal diseases research at Sanofi. He is currently a professor at the University of Copenhagen where his lab focuses on PNAs in regard to drug discovery, gene targeting, antisense principles, cellular and in vivo delivery and administration of biopharmaceuticals.

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52

XTalks

SEPTEMBER 20, 2024

XTALKS CLINICAL EDGE: Issue 3 — Interview with CTTI Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials. Such challenges highlight a significant unmet need and call for further advancements in the field.

Gene Editing 52

Gene Editing Manufacturing Gene In-Vivo 52

Roots Analysis

AUGUST 23, 2024

This adaptability was clear in coronavirus vaccine development using mRNA technology; after researchers had sequenced the virus’s RNA during January 2020, scientists were able create viable vaccine candidates within just months. This modern marvel wasn’t just used against COVID-19 but can be tailored now to fight any number of diseases.

Protein 40

Protein Vaccination Vaccine Immune Response 40

The Pharma Data

JANUARY 4, 2021

Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses. Barber is an associate professor of biology and director of the Office of Student Research. “We believe Prof. About PD-1 Check-point inhibition.

In-Vivo 40

In-Vivo Development Immune Response Big Data 40

XTalks

OCTOBER 1, 2020

WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation. Lin has made several transitions throughout her career, from being a clinician at an academic center, to academic research, to heading business development in industry. Motivations for Transition. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

The Pharma Data

DECEMBER 10, 2020

ImmunityBio has engineered the vector to overcome this problem and has shown that its second-generation adenovirus vector can safely and effectively deliver its cargo even in patients with pre-existing adenovirus immunity. This blocking of viral replication was observed in both the lung and nasal passages.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52